Sportradar shares take a hit after latest analyst move

Sportradar shares take a hit after latest analyst move

May 28, 2026

NEW YORK, May 28, 2026, 09:07 (EDT)

  • Sportradar ended Wednesday at $12.89 on Nasdaq, slipping 0.8%. The stock is down 45.8% for the year.
  • JPMorgan dropped its rating on the stock to Neutral from Overweight and cut the price target down to $16 from $26.
  • Investors are watching Sportradar Group AG face pressure after short-seller claims, a securities lawsuit, and an April denial from the company.

Sportradar Group AG is on watch Thursday as JPMorgan cut its rating on the sports data firm. The downgrade added to a steep 2026 selloff that has raised doubts about valuation, compliance issues, and how fast earnings can bounce back.

Sportradar Group AG shares finished Wednesday at $12.89 on Nasdaq, slipping 0.8%. That move came before U.S. markets opened Thursday. The stock has dropped around 46% since the start of the year, MarketScreener data show.

Wall Street’s focus has changed, and that’s key now. Sportradar is posting growth, but after last month’s short-seller reports about possible links to unregulated gambling groups—claims Sportradar denied—investors are now willing to pay less for that growth.

JPMorgan analyst Samuel Nielsen lowered Sportradar to Neutral from Overweight, StreetInsider reported. The bank also slashed its price target to $16 from $26, Investing.com said. Sportradar’s stock has de-rated to about 6 times FY27E EV/EBITDA from 11 times at 2025 year-end, according to the note. EV/EBITDA compares a company’s total value with earnings before interest, tax, depreciation and amortization, a measure of operating cash profit.

Analysts at Morgan are less upbeat on Sportradar, according to CDC Gaming. The team said in a note they see better short-term upside in other gaming names and don’t see a clear route for Sportradar’s valuation to move up soon. The analysts also wrote that the stock’s current price might already bake in a near worst-case scenario for its exposure to unregulated markets.

Sportradar’s first-quarter revenue came in at 347 million euros, up 11%. Adjusted EBITDA rose 12% to 66 million euros. The company posted a 6 million euro loss for the quarter, saying better operating results were offset by unrealized foreign exchange losses.

Sportradar CEO Carsten Koerl said in the April quarterly results that first-quarter growth showed the company’s “premier position” in sports data. Koerl added that increased buybacks and a bigger open-market repurchase program pointed to management’s “confidence in our trajectory.” Sportradar

Sportradar said it bought back $90 million of stock in the first quarter and set out a $250 million enhanced open-market repurchase program, part of its wider buyback effort. Buybacks can boost earnings per share by lowering the share count, but those moves don’t address regulatory or customer-quality concerns.

Sportradar is again in focus as investors look at the latest gaming-technology debate. JPMorgan lists the company alongside Genius Sports and Stats Perform, both named by Sportradar as sports data rivals. The note draws attention to data rights costs, operator demand, and regulatory risk.

Legal risk hasn’t gone away for the stock. Kessler Topaz says there’s a securities fraud class action in the Southern District of New York for investors who bought Sportradar between Nov. 7, 2024, and April 21, 2026. The complaint points to black-market gambling exposure.

Sportradar responded sharply. In a statement on April 22, it called the short seller reports “several factual inaccuracies” and said it only works with licensed operators. The company said it follows global compliance and due diligence standards, and stands behind its audited numbers and disclosures. Sportradar

The risks for Sportradar are clear. If regulators, customers or courts take the allegations seriously instead of seeing them as just a short-seller fight, Sportradar may have to deal with more compliance costs, slower sales, license checks or strain with betting firms and sports-rights partners. But if growth holds up and the legal worries ease, the low valuation flagged by JPMorgan could act as a floor instead of a warning sign.

Stock Market Today

  • GSK Shares Rise on Orphan Drug Status and $10.6 Billion Nuvalent Oncology Deal
    June 12, 2026, 9:13 AM EDT. GSK shares rose 1.32% after momelotinib earned Orphan Drug Designation from the US FDA and European Medicines Agency for VEXAS syndrome, a rare inflammatory disorder. This designation offers development incentives but does not authorize sales. The boost follows GSK's $10.6 billion acquisition of Nuvalent, adding late-stage lung cancer drugs zidesamtinib and neladalkib, with FDA decisions due by November 2026. GSK posted 5% sales growth in Q1 2026, driven by Specialty Medicines up 14% and oncology up 28%. The company aims for 3%-5% turnover growth and 7%-9% profit rise in 2026 but faces patent expiry and integration risks from the Nuvalent deal. Investors focus on upcoming ATLAS trial data and regulatory milestones for pipeline momentum.